68-4

92/136

4) Gröbner SN, Worst BC, Weischenfeldt J, et al: The land-scape of genomic alterations across childhood cancers. Nature, 2018; 555: 321-327. 5) Yamaguchi-Kabata Y, Yasuda J, Tanabe O, et al: Eval-uation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. J Hum Genet, 2018; 63: 213-230. 6) Bougeard G, Renaux-Petel M, Flaman JM, et al: Revis-iting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol, 2015; 33: 2345-2352. 7) Mai PL, Best AF, Peters JA, et al: Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer, 2016; 122: 3673-3681. 8) Renaux-Petel M, Charbonnier F, Théry JC, et al: Contri-bution of de novo and mosaic TP53 mutations to Li- Fraumeni syndrome. J Med Genet, 2018; 55: 173-180. 9) Gonzalez K, Noltner K, Buzin C: Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol, 2009; 27: 1250-1256.10) Kumamoto T, Yamazaki F, Nakano Y, et al: Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol, 2021; 26: 2161-2178.11) Momozawa Y, Iwasaki Y, Parsons MT, et al: Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun, 2018; 9: 4083.12) Trombetta MG, Dragun A, Mayr NA, Pierce LJ: ASTRO Radiation Therapy Summary of the ASCO-ASTRO- SSO Guideline on Management of Hereditary Breast Cancer. Pract Radiat Oncol, 2020; 10: 235-242.13) Daly MB, Pal T, Berry MP, et al: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancre-atic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021; 19:77-102.14) Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al: Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer, 2012; 118: 908- 913.15) Thariat J, Chevalier F, Orbach D, et al: Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer 412syndromes. Lancet Oncol, 2021; 22: e562-e574.16) Marinovich ML, Azizi L, Macaskill P, et al: The Associ-ation of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol, 2016; 23: 3811-3821.17) Adlard J, Burton C, Turton P: Increasing Evidence for the Association of Breast Implant-Associated Anaplastic Large Cell Lymphoma and Li Fraumeni Syndrome. Case Rep Genet, 2019; 2019: 5647940.18)Wang H, Xie C, Li S, et al: Dysregulation, But Not Mutation Of p53 Signaling Pathway In Breast Implant- Associated Anaplastic Large Cell Lymphoma Cell Lines. Blood, 2013; 122: 4879-4879.19) Toguchida J, Yamaguchi T, Dayton SH, et al: Preva-lence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med, 1992; 326: 1301-1308.20) Zerdoumi Y, Lanos R, Raad S, et al: Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet, 2017; 26: 2812.21) de Andrade KC, Khincha PP, Hatton JN, et al: Cancer incidence, patterns, and genotype-phenotype associa-tions in individuals with pathogenic or likely patho-genic germline TP53 variants: an observational cohort study. Lancet Oncol, 2021; 22: 1787-1798.22) Rana HQ, Clifford J, Hoang L, et al: Genotype-pheno-type associations among panel-based TP53+ subjects. Genet Med, 2019; 21: 2478-2484.23) Ballinger ML, Best A, Mai PL, et al: Baseline Surveil-lance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol, 2017; 3: 1634-1639.24) McBride KA, Ballinger ML, Schlub TE, et al: Psychoso-cial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer, 2017; 16: 423-432.25) Grasparil AD, 2nd, Gottumukkala RV, Greer MC, Gee MS: Whole-Body MRI Surveillance of Cancer Predis-position Syndromes: Current Best Practice Guidelines for Use, Performance, and Interpretation. AJR Am J Roentgenol, 2020; 215: 1002-1011.